{"version":"1.0","provider_name":"South Africa Gazette","provider_url":"https:\/\/southafricagazette.com","author_name":"shadmin","author_url":"https:\/\/southafricagazette.com\/author\/shadmin-s\/","title":"First CE-IVD marked AI solution for prognostic risk stratification of breast cancer patients. - South Africa Gazette","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"gQjerUNptK\"><a href=\"https:\/\/southafricagazette.com\/first-ce-ivd-marked-ai-solution-for-prognostic-risk-stratification-of-breast-cancer-patients\/\">First CE-IVD marked AI solution for prognostic risk stratification of breast cancer patients.<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/southafricagazette.com\/first-ce-ivd-marked-ai-solution-for-prognostic-risk-stratification-of-breast-cancer-patients\/embed\/#?secret=gQjerUNptK\" width=\"600\" height=\"338\" title=\"&#8220;First CE-IVD marked AI solution for prognostic risk stratification of breast cancer patients.&#8221; &#8212; South Africa Gazette\" data-secret=\"gQjerUNptK\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/* ]]> *\/\n<\/script>\n","description":"Stratipath, a global leader in AI-based precision diagnostic solutions, today announced that its AI software for prognostic risk stratification of breast cancers, Stratipath Breast, is now CE-IVD marked. Stockholm, Sweden, June 01, 2022 (GLOBE NEWSWIRE) \u2014 Stratipath,\u00a0a global leader in AI-based precision diagnostic solutions, today announced that\u00a0its\u00a0AI software for prognostic risk stratification of breast cancers,\u00a0Stratipath [\u2026]","thumbnail_url":"https:\/\/ci4.googleusercontent.com\/proxy\/VCeJBDxSrIIF-O6KsBymlxA3I1tyHUh964pB0Zap5sq6MzF79MRfqjaaYW3FQEhm7JqIbHaKDfj6LG9qb6WbjhlPTlP5sx89ExyUGuOCABfGwKmh65xQWQo8KcyXxFUzXSkGEP6rTZ9hpSHOJGrVFH_FPSwXIA5oJ1-0LwiGhvhpX52KUVg=s0-d-e1-ft#https:\/\/ml.globenewswire.com\/media\/N2UyODlkZGYtZjg5ZS00MGZiLTg3NWUtMzE5MDcwOWJmMmE0LTEyNjA0MjE=\/tiny\/Stratipath.png"}